1. Cervix cancer screening. IARC Handbooks of cancer prevention. Vol. 10. Lyon, France: International Agency for Research on Cancer, 2005 (https://publications .iarc.fr/380).
2. WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention. Geneva: World Health Organization, 2021.
3. Preamble for secondary prevention. IARC handbooks of cancer prevention. Lyon, France: International Agency for Research on Cancer, 2019 (https://handbooks .iarc.fr/docs/HB-Preamble-Secondary-Prevention.pdf).
4. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020; 8(2): e191-e203.
5. Global cancer observatory. Lyon, France: International Agency for Research on Cancer, 2018 (https://gco .iarc.fr/).
6. Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2021; 9(2): e161-e169.
7. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2: 16086.
8. Serrano B, Roura E, Guijarro P, et al. National cervical cancer screening programs and coverage worldwide. Presented at the 33rd International Papillomavirus Conference, virtual, July 20–24, 2020.
9.Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008; 5(6): e132.
10. Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health 2015; 3(2): e85-e94.
11. Cervical cancer screening. IARC handbooks of cancer prevention. Vol. 18. Lyon, France: International Agency for Research on Cancer (in press).
12.Sankaranarayanan R, Nene BM, Dinshaw KA, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005; 116: 617-23.
13. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
14. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2013;2:35–35.
15. Obwegeser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases. Acta Cytol 2001; 45: 709-14.
16. Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TC Jr. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer 2006; 118: 957-62.
17. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007; 335: 28.
18. Strander B, Andersson-Ellstrom A, Milsom I, Radberg T, Ryd W. Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program: a prospective randomized study. Cancer 2007; 111: 285-91.
19.Maccallini V, Angeloni C, Caraceni D, et al. Comparison of the conventional cervical smear and liquid-based cytology: results of a controlled, prospective study in the Abruzzo Region of Italy. Acta Cytol 2008; 52: 568-74.
20. Sykes PH, Harker DY, Miller A, et al. A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting. BJOG 2008; 115: 1375-81.
21. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009; 302: 1757-64.
22. Klug SJ, Neis KJ, Harlfinger W, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer 2013; 132: 2849-57.
23. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406.
24. Shastri SS, Mittra I, Mishra GA, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106(3): dju009.
25. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005; 294: 2173-81.
26. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524- 32.
27. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87.
28. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010; 21: 1323-60.
29. Bruni L, Albero G, Serrano B, et al. Human papillomavirus and related diseases report. Summary report 17 June 2019. Barcelona: L’Hospitalet de Llobregat, 2019
30. Korfage IJ, van Ballegooijen M, Wauben B, Looman CW, Habbema JD, Essink-Bot ML. Having a Pap smear, quality of life before and after cervical screening: a questionnaire study. BJOG 2012; 119: 936-44.
31. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect 2017; 93: 56-61.
32. Arrossi S, Almonte M, Herrero R, et al. Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study. Prev Med Rep 2020; 18: 101070.
33. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017; 11(11): CD012847.
34. Monitoring national cervical cancer prevention and control programmes: quality control and quality assurance for visual inspection with acetic acid (VIA)-based programmes. Geneva: World Health Organization, 2013 (https://apps .who.int/iris/handle/10665/79316).
35. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
36. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
37. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
38. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA 2018; 320: 43-52.
39. Leinonen MK, Nieminen P, Lonnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012; 345: e7789.
40. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med 2017; 14(9): e1002388.
41. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
42. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
43. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009; 13: 1-150.
44. Chan KKL, Liu SS, Wei N, et al. Primary HPV testing with cytology versus cytology alone in cervical screening — a prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer 2020; 147: 1152-62.
45. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016; 76: Suppl 1: S49-S55.
46. Denny L, Kuhn L, Hu C-C, Tsai W-Y, Wright TC Jr. Human papillomavirus- based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010; 102: 1557-67.
47. Sarian LO, Derchain S, Shabalova I, et al. Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe. J Med Screen 2010; 17: 195-203.
48. Asthana S, Labani S. Adjunct screening of cervical or vaginal samples using careHPV testing with Pap and aided visual inspection for detecting high-grade cervical intraepithelial neoplasia. Cancer Epidemiol 2015; 39: 104-8.
49. Basu P, Mittal S, Banerjee D, et al. Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India. Int J Cancer 2015; 137: 859-67.
50. Zhao YQ, Dai Y, Dang L, et al. Real-world research on cervical cancer screening program and effect evaluation for Chinese population. Zhonghua Zhong Liu Za Zhi 2018; 40: 764-71. (In Chinese.)
51. Bhatla N, Gulati A, Mathur SR, et al. Evaluation of cervical screening in rural North India. Int J Gynaecol Obstet 2009; 105: 145-9.
52. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30: Suppl 5: F88-F99.
53. Elfstrom KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014; 348: g130.
54. Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 2016; 355: i4924.
55. Han L, Chang X, Song P, et al. An on-going study of three different cervical cancer screening strategies based on primary healthcare facilities in Beijing China. J Infect Public Health 2020; 13: 577-83.
56. Schiffman M, Kinney WK, Cheung LC, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 2018; 110: 501-8.
57. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014; 106(8): dju153.
58. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018; 363: k4823.
59. El-Zein M, Bouten S, Louvanto K, et al. Validation of a new HPV self-sampling device for cervical cancer screening: the Cervical and Self-Sample In Screening (CASSIS) study. Gynecol Oncol 2018; 149: 491-7.
60. Polman NJ, Ebisch RMF, Heideman DAM, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screenpositive, non-inferiority trial. Lancet Oncol 2019; 20: 229-38.
61. Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. BMJ Open 2019; 9(4): e025388.
62. Zhang L, Xu X-Q, Hu S-Y, et al. Durability of clinical performance afforded by self-collected HPV testing: a 15-year cohort study in China. Gynecol Oncol 2018; 151: 221-8.
63. Cook DA, Smith LW, Law JH, et al. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. J Clin Virol 2018; 108: 32-7.
64. Forslund O, Miriam Elfstrom K, Lamin H, Dillner J. HPVmRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. Int J Cancer 2019; 144: 1073-81.
65. Iftner T, Neis K-J, Castanon A, et al. Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based Hybrid Capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol 2019; 57(1): e01177-18.
66. Zorzi M, Del Mistro A, Giorgi-Rossi P, et al. Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow-up. Int J Cancer 2020; 146: 3114-23.
67. Pankakoski M, Anttila A, Sarkeala T, Heinavaara S. Effectiveness of cervical cancer screening at age 65 — a registerbased cohort study. PLoS One 2019; 14(3): e0214486.
68. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV 2018; 5(1): e45-e58.
69. Rohner E, Butikofer L, Schmidlin K, et al. Cervical cancer risk in women living with HIV across four continents: a multicohort study. Int J Cancer 2020; 146: 601-9.
70. Kelly HA, Chikandiwa A, Sawadogo B, et al. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: a cohort study. PLoS Med 2021; 18(3): e1003528.
71. Luckett R, Mogowa N, Li HJ, et al. Performance of two-stage cervical cancer screening with primary high-risk human papillomavirus testing in women living with human immunodeficiency virus. Obstet Gynecol 2019; 134: 840-9.
72. Firnhaber C, Mayisela N, Mao L, et al. Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One 2013; 8(1): e53494.
73. Arrossi S, Paolino M, Laudi R, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before- and-after retrospective cohort study. Lancet Glob Health 2019; 7(6): e772-e783.